status: 200
content-location: http://rest.kegg.jp/get/path:map05223
server: Apache
date: Wed, 15 Oct 2014 14:59:12 GMT
content-type: text/plain

ENTRY       map05223                    Pathway
NAME        Non-small cell lung cancer
DESCRIPTION Lung cancer is a leading cause of cancer death among men and women in industrialized countries. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer and represents a heterogeneous group of cancers, consisting mainly of squamous cell (SCC), adeno (AC) and large-cell carcinoma. Molecular mechanisms altered in NSCLC include activation of oncogenes, such as K-RAS, c-erbB-2 and EML4-ALK, and inactivation of tumorsuppressor genes, such as p53, p16INK4a, RAR-beta, and RASSF1. Point mutations within the K-RAS gene inactivate GTPase activity and the p21-RAS protein continuously transmits growth signals to the nucleus. Overexpression of c-erbB-2 or EGFR leads to a proliferative advantage. EML4-ALK fusion leads to constitutive ALK activation, which causes cell proliferation, invasion, and inhibition of apoptosis. Inactivating mutation of p53 can lead to more rapid proliferation and reduced apoptosis. The protein encoded by the p16INK4a  inhibits formation of CDK-cyclin-D complexes by competitive binding of CDK4 and CDK6. Loss of p16INK4a expression is a common feature of NSCLC. RAR-beta is a nuclear receptor that bears vitamin-A-dependent transcriptional activity. RASSF1A is able to form heterodimers with Nore-1, an RAS effector.Therefore loss of RASSF1A might shift the balance of RAS activity towards a growth-promoting effect.
CLASS       Human Diseases; Cancers
PATHWAY_MAP map05223  Non-small cell lung cancer
DISEASE     H00014  Non-small cell lung cancer
REFERENCE   PMID:12379883
  AUTHORS   Osada H, Takahashi T.
  TITLE     Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer.
  JOURNAL   Oncogene 21:7421-34 (2002)
REFERENCE   PMID:12741677
  AUTHORS   Yokota J, Nishioka M, Tani M, Kohno T.
  TITLE     Genetic alterations responsible for metastatic phenotypes of lung cancer cells.
  JOURNAL   Clin Exp Metastasis 20:189-93 (2003)
REFERENCE   PMID:16870043
  AUTHORS   Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.
  TITLE     K-ras mutations in non-small-cell lung carcinoma: a review.
  JOURNAL   Clin Lung Cancer 8:30-8 (2006)
REFERENCE   PMID:15948711
  AUTHORS   Pfeifer GP, Dammann R.
  TITLE     Methylation of the tumor suppressor gene RASSF1A in human tumors.
  JOURNAL   Biochemistry (Mosc) 70:576-83 (2005)
REFERENCE   PMID:11902573
  AUTHORS   Altucci L, Gronemeyer H.
  TITLE     The promise of retinoids to fight against cancer.
  JOURNAL   Nat Rev Cancer 1:181-93 (2001)
REFERENCE   PMID:10944551
  AUTHORS   Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF.
  TITLE     Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas.
  JOURNAL   J Natl Cancer Inst 92:1303-7 (2000)
REFERENCE   PMID:12867060
  AUTHORS   Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA.
  TITLE     Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
  JOURNAL   Lung Cancer 41 Suppl 1:S29-42 (2003)
REFERENCE   PMID:16112428
  AUTHORS   Panani AD, Roussos C.
  TITLE     Cytogenetic and molecular aspects of lung cancer.
  JOURNAL   Cancer Lett 239:1-9 (2006)
REFERENCE   PMID:12407699
  AUTHORS   Mitsuuchi Y, Testa JR.
  TITLE     Cytogenetics and molecular genetics of lung cancer.
  JOURNAL   Am J Med Genet 115:183-8 (2002)
REFERENCE   PMID:15942304
  AUTHORS   Breuer RH, Postmus PE, Smit EF.
  TITLE     Molecular pathology of non-small-cell lung cancer.
  JOURNAL   Respiration 72:313-30 (2005)
REFERENCE   PMID:11895903
  AUTHORS   Piyathilake CJ, Frost AR, Manne U, Weiss H, Bell WC, Heimburger DC, Grizzle WE.
  TITLE     Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung.
  JOURNAL   Clin Cancer Res 8:734-44 (2002)
REFERENCE   PMID:16189154
  AUTHORS   Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K.
  TITLE     Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
  JOURNAL   J Clin Pathol 58:1076-80 (2005)
REFERENCE   PMID:17625570
  AUTHORS   Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H
  TITLE     Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
  JOURNAL   Nature 448:561-6 (2007)
REFERENCE   PMID:18593892
  AUTHORS   Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Hamada T, Haruta H, Watanabe H, Kurashina K, Hatanaka H, Ueno T, Takada S, Yamashita Y, Sugiyama Y, Ishikawa Y, Mano H
  TITLE     Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.
  JOURNAL   Cancer Res 68:4971-6 (2008)
REFERENCE   PMID:19629074
  AUTHORS   Janne PA, Gray N, Settleman J
  TITLE     Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
  JOURNAL   Nat Rev Drug Discov 8:709-23 (2009)
REFERENCE   PMID:23201355
  AUTHORS   Roskoski R Jr
  TITLE     Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
  JOURNAL   Pharmacol Res 68:68-94 (2013)
REFERENCE   PMID:22154278
  AUTHORS   Reungwetwattana T, Weroha SJ, Molina JR
  TITLE     Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC).
  JOURNAL   Clin Lung Cancer 13:252-66 (2012)
REFERENCE   PMID:21855164
  AUTHORS   Popat S, Gonzalez D, Min T, Swansbury J, Dainton M, Croud JG, Rice AJ, Nicholson AG
  TITLE     ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.
  JOURNAL   Lung Cancer 75:300-5 (2012)
REFERENCE   PMID:21753699
  AUTHORS   Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K, Tsuda H
  TITLE     Comprehensive histologic analysis of ALK-rearranged lung carcinomas.
  JOURNAL   Am J Surg Pathol 35:1226-34 (2011)
REFERENCE   PMID:22736493
  AUTHORS   Shaozhang Z, Xiaomei L, Aiping Z, Jianbo H, Xiangqun S, Qitao Y
  TITLE     Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
  JOURNAL   Genes Chromosomes Cancer 51:925-32 (2012)
KO_PATHWAY  ko05223
///
